35 completed, 10 recruiting, 10 unknown, 9 active not recruiting. 39 Phase 2, 29 Phase 3, 6 Phase 1, 4 Not applicable, 2 Early Phase 1.
Follow CP protocol: new trials by email Literature Review of CP protocol trials Research Report on CP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial Paclitaxel + Carboplatin, Pembrolizumab - Triple Negative Breast Cancer, Blood and Image Guided | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2026-11-05 | 2026-05-28 |
| Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Carboplatin, Bevacizumab - Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 176 | 2026-09-30 | 2026-08-20 |
| Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer Eftilagimod Alfa (Efti), Docetaxel-cyclophosphamide (TC) intravenous (i.v), Dose dense Adriamycin-cyclophosphamide (AC) i.v - Breast Cancer, HER 2 Negative Breast Cancer | Phase 2 | Not yet recruiting | George Washington University | 50 | 2026-09-01 | 2026-06-11 |
| HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion HSK41959, Sintilimab, Pemetrexed + Cisplatin /Carboplatin - Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC) | Phase 1 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 258 | 2026-07-01 | 2026-07-14 |
| Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer medroxyprogesterone acetate tablets OR megestrol acetate, Cisplatin, Carboplatin + Paclitaxel - Endometrial Cancer, Uterine Neoplasms | Phase 3 | Recruiting | University College, London | 600 | 2026-06-29 | 2026-09-21 |
| A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. EIK1001, Pembrolizumab (KEYTRUDA®), Placebo - Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC | Phase 2 / Phase 3 | Recruiting | Eikon Therapeutics | 750 | 2026-06-15 | 2026-11-03 |
| SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） SYS6010 injection, Enlonstobart injection, Tislelizumab injection - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 500 | 2026-06-02 | 2026-06-11 |
| Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer Hypofractionation, carboplatin + paclitaxel (CP) - Locally Advanced Esophageal or GE Junction Cancer | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 60 | 2026-04-28 | 2026-06-08 |
| The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression Paclitaxel, Paclitaxel + Carboplatin - Ovarian Cancer | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 60 | 2026-01-31 | 2026-02-10 |
| A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients SSGJ-706, pemetrexed /carboplatin, Carboplatin/Paclitaxel - First-line Advanced NSCLC Patients | Phase 2 | Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 240 | 2025-10-24 | 2025-12-18 |
| Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer Camrelizumab, Doxorubicin +cyclophosphamide+ filgrastimum, carboplatin + paclitaxel (CP) - Breast Cancer | Phase 2 | Not yet recruiting | Blokhin's Russian Cancer Research Center | 40 | 2025-08-01 | 2025-08-17 |
| Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer Cyclophosphamide+Pemetrexed+5-Fluorouracil, Cyclophosphamide+Doxorubicin+5-Fluorouracil, Vindesine + Cisplatin - Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | West China Hospital | 20 | 2024-12-01 | 2024-12-03 |
| Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Cadonilimab, radiotherapy, carboplatin, paclitaxel - Locally Advanced Esophageal Squamous Cell Carcinoma, II-IIIB Stages | Not applicable | Enrolling by invitation | First Affiliated Hospital of Ningbo University | 20 | 2024-12-01 | 2025-03-25 |
| Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin - Endometrial Carcinoma | Not applicable | Completed | Sohag University | 60 | 2024-08-15 | 2026-05-22 |
| Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Carboplatin/Paclitaxel, Pembrolizumab, Partial or total penectomy with inguinal and/or pelvic lymph node dissection - Urologic Neoplasms, Urogenital Neoplasms | Phase 2 | Recruiting | The Netherlands Cancer Institute | 27 | 2024-08-13 | 2025-12-08 |
| A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin - Non-Small Cell Lung Cancer With HER2- Mutations | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 300 | 2024-07-29 | 2026-01-21 |
| Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy Standard Chemotherapy (Carboplatin-Paclitaxel) - Ovarian Cancer (OvCa), Fallopian Tube Cancers | Completed | Ankara Etlik City Hospital | 102 | 2024-03-15 | 2025-09-04 | |
| Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin - Melanoma | Phase 3 | Recruiting | Shanghai Kechow Pharma, Inc. | 165 | 2023-11-02 | 2024-06-28 |
| Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients paclitaxel/carboplatin - Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Yonsei University | 79 | 2023-05-26 | 2026-05-26 |
Showing 20 of 80. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (18) · Ovarian Neoplasms (13) · Breast Neoplasms (9) · Carcinoma, Ovarian Epithelial (6) · Fallopian Tube Neoplasms (6) · Endometrial Neoplasms (5) · Esophageal Squamous Cell Carcinoma (4) · Squamous Cell Carcinoma of Head and Neck (4) · Carcinoma (3) · Lung Neoplasms (3) · Neoplasm Metastasis (3) · Triple Negative Breast Neoplasms (3) · Uterine Neoplasms (3) · Adenocarcinoma (2) · Esophageal Neoplasms (2)
AstraZeneca (8) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Fudan University (2) · Shanghai Jiao Tong University School of Medicine (2) · Zhejiang Cancer Hospital (2) · AGO Study Group (1) · ARCAGY/ GINECO GROUP (1) · Abbott (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Ankara Etlik City Hospital (1) · Asan Medical Center (1) · Bayer (1) · Beijing Protgen Biotechnology Development Co., Ltd. (1) · Blokhin's Russian Cancer Research Center (1) · Bristol-Myers Squibb (1)
China (26) · United States (22) · South Korea (14) · France (13) · Canada (11) · Germany (10) · Belgium (9) · Poland (9) · Hungary (8) · Italy (8) · Netherlands (8) · Spain (8) · United Kingdom (8) · Australia (7) · Japan (7)
Adnan Munkarah, MD (1) · Alessandro D Santin, M.D. (1) · Alwin Kraemer, Prof. Dr. (1) · Andreas Obermair (1) · Andreas du Bois, MD, PhD (1) · Bent Ejlertsen, M.D. (1) · Caigang Liu, M.D., Ph.D. (1) · Carol Aghajanian (1) · Clinton Yam, MD (1) · Dr Johann de Bono, MD (1) · E. Pujade-Lauraine, MD, PhD (1)
PMID 11020574, PMID 15169803, PMID 15459211, PMID 15913742, PMID 16330675, PMID 19349552, PMID 19767092, PMID 1989916, PMID 20211870, PMID 20733132, PMID 21410972, PMID 21436701, PMID 21508697, PMID 21831418, PMID 2211199, PMID 2211200, PMID 22248721, PMID 2258085, PMID 2323606, PMID 23642625, PMID 2380095, PMID 23948349, PMID 24114964, PMID 2412690, PMID 24356636, PMID 24724218, PMID 25541155, PMID 25578377, PMID 26493267, PMID 27067521, PMID 2745205, PMID 29584549, PMID 3053592, PMID 30785829, PMID 31637669, PMID 31667659, PMID 31912673, PMID 32271377, PMID 32601075, PMID 33084020, PMID 33235314, PMID 33775558, PMID 35298906, PMID 35912196, PMID 36806898, PMID 37185961, PMID 37407274, PMID 37489066, PMID 38468440, PMID 39442040
2015 (2), 2017 (2), 2018 (2), 2005 (1), 2016 (1), 2023 (1), 2025 (1)